AI Article Synopsis
- Hepatocellular adenoma (HCA) is a rare and benign liver tumor often found incidentally, commonly linked to oral contraceptive use or pregnancy.
- Treatment usually involves conservative management for smaller tumors (<5 cm) and surgical resection for larger tumors (>5 cm) that carry higher risks.
- Recent advancements in molecular subclassification of HCA based on morphological features and marker expressions may enhance patient stratification and guide treatment decisions.
Article Abstract
Hepatocellular adenoma (HCA) is a rare, benign liver tumor. Discovery of this tumor is usually as an incidental finding, correlated with the use of oral contraceptives, or pregnancy. Treatment options have focused on conservative management for the straightforward, smaller lesions (<5 cm), with resection preferred for larger lesions (>5 cm) that pose a greater risk of hemorrhage or malignant progression. In recent years, a new molecular subclassification of HCA has been proposed, associated with characteristic morphological features and loss or increased expression of immunohistochemical markers. This subclassification could possibly provide considerable benefits in terms of patient stratification, and the selection of treatment options. In this review we discuss the decision-making processes and associated risk analyses that should be made based on lesion size, and subtype. The usefulness of this subclassification system in terms of the procedures instigated as part of the diagnostic work-up of a suspected HCA will be outlined, and suitable treatment schemes proposed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5076773 | PMC |
| http://dx.doi.org/10.1177/1756283X16663882 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A comprehensive study on the feasibility and diagnostic potential of fluctuation imaging in liver tumor assessment.
Sci Rep
December 2024
Department of Radiology, Seoul National University Hospital, 101 Daehangno, Jongno-gu, Seoul, 03080, Korea.
Ultrasound (US) is a widely used technique for liver disease but has limitations in distinguishing tumors. This study evaluates the clinical efficacy of fluctuational imaging (FLI), a new US method that detects the fluttering sign in liver tumors. We conducted a prospective exploratory study with 120 participants diagnosed with liver tumors through histopathology or standard imaging.
View Article and Find Full Text PDFImmunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypes.
Front Nucl Med
November 2024
Department of Radiology, Mayo Clinic, Rochester, MN, United States.
Article Synopsis
- This study investigates the expression and location of fibroblast activation protein (FAP) in various liver tumors, focusing on cholangiocarcinoma (CCA), hepatocellular carcinoma (HCC), hepatocellular adenoma (HCA), and focal nodular hyperplasia (FNH).
- FAP immunostaining results showed that a high percentage of CCA exhibited moderate to strong FAP expression compared to other tumor types, indicating a significant distinction.
- The findings suggest that FAP is consistently present in CCA tumor stroma regardless of clinical features, highlighting its potential as a target for future diagnostic and therapeutic strategies in treating different CCA subtypes.
[F]AlF-NOTA-pentixather PET/CT of CXCR4 in patients with suspected primary hyperaldosteronism.
Theranostics
December 2024
Department of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Distinguishing unilateral aldosterone-producing adenomas (APA) from idiopathic hyperaldosteronism (IHA), nonfunctional adrenal adenoma (NFA), and pheochromocytoma (PHEO) within primary aldosteronism (PA) presents a significant challenge. Studies have demonstrated high levels of chemokine receptor (CXCR) 4 expression in APA, thereby validating the use of Ga-labeled CXCR4 PET/CT for detecting APA. This study evaluates the efficacy of [F]AlF-NOTA-pentixather PET/CT in distinguishing APA from other PA types.
View Article and Find Full Text PDFHepatocellular Adenoma: A Life-Threatening Presentation of a Rare Liver Tumor - Case Report and Literature Review.
GE Port J Gastroenterol
December 2024
Gastrenterology Department, Centro Hospitalar de Setúbal, Setúbal, Portugal.
Article Synopsis
- Hepatocellular adenoma is a rare, benign liver tumor mostly found in young women using hormonal contraceptives, particularly estrogen.
- A 40-year-old woman experienced severe right upper abdominal pain and instability due to a large bleeding adenoma, which was managed with arterial embolization and then surgical resection.
- The case emphasizes the importance of considering hepatocellular adenoma in younger women on birth control who have severe abdominal pain, highlighting the need for awareness and proper management strategies for this condition.
Preoperative blood tests provide diagnostic and prognostic information about patients with hepatocellular carcinoma.
Eur J Gastroenterol Hepatol
February 2025
Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Royal Free Hospital, Royal Free London NHS Foundation Trust, London, UK.
Introduction: Our aim was to assess parameters derived from preoperative blood tests as diagnostic or prognostic markers in patients with operable hepatocellular carcinoma (HCC).
Methods: We included 210 patients who underwent liver resection as the first treatment for suspected hepatocellular adenoma (HCA) or HCC (January 2010-December 2022). Parameters originated from preoperative complete blood count and biochemical blood tests were examined for associations with clinicopathological parameters and survival.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!